Agfa-Gevaert cuts outlook

Article

Sales rose about 9% in the second quarter for Agfa-Gevaert, but the good news may not last. The company warned that profits are falling short of expectations due to higher exceptional expenses and to production and administrative costs. Profits may not

Sales rose about 9% in the second quarter for Agfa-Gevaert, but the good news may not last. The company warned that profits are falling short of expectations due to higher exceptional expenses and to production and administrative costs. Profits may not return to previous levels until sometime next year. Executives expect to release a plan to regain profitability on Sept. 27. The plan will focus on efficiency and cost-effectiveness but will not alter the company’s strategy of further expansion and acquisition in digital imaging.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.